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ABSTRACT
NOD-like receptor (NLR) NLRP3 inflammasome activation has been implicated in 
the progression of non-alcoholic fatty liver disease (NAFLD) from non-alcoholic fatty liver 
(NAFL) to non-alcoholic steatohepatitis (NASH). It has been also shown that palmitic 
acid (PA) activates NLRP3 inflammasome and promotes interleukin-1β (IL-1β) secretion 
in Kupffer cells (KCs). However, the specific mechanism of the NLRP3 inflammasome 
activation is unclear. We studies the molecular mechanisms by investigating the roles of 
Thioredoxin-interacting protein (TXNIP) and NLRP3 on NAFLD development in patients, 
high-fat diet (HFD)-induced NAFL and methionine choline deficient (MCD) diet-induced 
NASH in wild type (WT), TXNIP−/− (thioredoxin-interacting protein) and NLRP3−/− mice, 
and isolated KCs. We found that the expressions of NLRP3 and TXNIP in human liver tissues 
were higher in NASH group than in NAFL group. Furthermore, co-immunoprecipitation 
analyses show that activation of the TXNIP-NLRP3 inflammasome protein complex 
occurred in KCs of NASH WT mice rather than NAFL WT mice, thus suggesting that the 
formation and activation of this protein complex is mainly involved in the development 
of NASH. NLRP3−/− mice exhibited less severe NASH than WT mice in MCD diet model, 
whereas TXNIP deficiency enhanced NLRP3 inflammasome activation and exacerbated 
liver injury. PA triggered the activation and co-localization of the NLRP3 inflammasome 
protein complex in KCs isolated from WT and TXNIP−/− but not NLRP3−/− mice, and most 
of the complex co-localized with mitochondria of KCs following PA stimulation. Taken 
together, our novel findings indicate that TXNIP plays a protective and anti-inflammatory 
role in the development of NAFLD through binding and suppressing NLRP3.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is 
considered to be the main hepatic manifestation of 
metabolic syndrome, and is currently the most common 
cause of chronic liver disease in many developed and 
developing countries worldwide [1, 2]. NAFLD ranges 
from hepatic steatosis or non-alcoholic fatty liver (NAFL), 
which is characterized by the accumulation of triglycerides 
in hepatocytes, to non-alcoholic steatohepatitis (NASH), 
which can eventually progress to end-stage liver diseases 
such as cirrhosis and hepatocellular carcinoma [1, 3]. 
The pathogenesis of NAFLD is commonly based on 
the ‘double-hit’ hypothesis, which was proposed by 
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Day and James in 1998 [4]. According to this theory, 
the initial hepatocellular lipid accumulation represents 
the ‘first hit’, followed by a “second hit”, in which 
pro-inflammatory mediators induce inflammation and 
hepatocellular injury, thus promoting the progression to 
NASH. Recently, increasing emphasis has been placed on 
the mechanisms underlying the progression from NAFL 
to NASH, which has been deemed the crucial step in 
the development of NAFLD [5]. It is currently thought 
that the genesis and development of NASH are closely 
related to metaflammation, a low-grade form of chronic 
inflammation that is mainly involved in the “second 
hit” [6]. However, the exact mechanism underlying the 
development of NASH remains to be clearly defined.
NLRP3 is the best characterized member of the 
inflammasome family. It consists of the NOD-like 
receptor (NLR) NLRP3, the adaptor molecule apoptosis-
associated speck-like protein containing a caspase 
recruitment domain (ASC) and the effector molecule pro-
caspase-1 [7]. NLRP3 inflammasome activation is a two-
step process [8]. The first step consists of cell priming with 
an NF-κB activator, leading to the up-regulation of NLRP3 
and pro-IL-1β expression, and the second step includes a 
broad variety of activators, such as free fatty acid (FFA), 
which induces NLRP3 inflammasome activation [8]. 
The key step in NLRP3 inflammasome activation is the 
cleavage and activation of Caspase-1, which subsequently 
activates pro-IL-1β to IL-1β, and has been shown to play 
an essential role in the formation of NASH [9, 10].
Importantly, high plasma levels of saturated FFAs, 
such as palmitic acid (PA), which has been suggested to 
trigger inflammation and contribute to the development of 
NASH, have been reported in mice models of methionine 
choline deficient (MCD) diet-induced NASH and NASH 
patients [11]. Kupffer cells (KCs) are the liver-derived 
macrophages that represent approximately 80–90% of 
the tissue resident macrophages [12, 13]. KCs have been 
implicated in the pathogenesis of various liver diseases, such 
as NASH, alcoholic liver disease and liver fibrosis, and are 
thought to contribute to liver rejection after transplantation 
[14–16]. KCs have been described as the primary site of 
NLRP3 inflammasome activation and the source of the 
pro-inflammatory cytokine IL-1β in liver tissues [17]. 
Thioredoxin-interacting protein (TXNIP, also known as 
VDUP1), which has been implicated in many metabolic 
diseases, is an essential intermediate that is associated 
with NLRP3 activation through binding to NLRP3 in a 
reactive oxygen species (ROS)-dependent manner after 
its detachment from thioredoxin (TRX) [18]. In addition, 
mitochondria are the main cellular source of ROS, which 
have been proven to form a central component proximal 
to NLRP3 inflammasome activation [19, 20]. However, 
the roles of the TXNIP and NLRP3 inflammasome in the 
progression of NAFLD are controversial and the precise 
mechanism underlying NLRP3 inflammasome activation 
through TXNIP in KCs remains to be evaluated [21].
In this study, we explored the roles and relationship 
of TXNIP and NLRP3 in NLRP3 inflammasome activation 
in NAFLD patients, high-fat diet (HFD)-induced NAFL 
and MCD diet-induced NASH in wild type (WT), TXNIP 
knockout (TXNIP−/−) and NLRP3−/− mice, and in isolated 
KCs.
RESULTS
NASH patients presented increased expressions 
of NLRP3 and TXNIP and increased pro-
inflammatory cytokine IL-1β levels 
We examined the serological and liver pathological 
changes in patients with NAFL and NASH. The patient 
characteristics are summarized in Table 1. There were no 
significant differences in alanine aminotransferase (ALT), 
aspartate transaminase (AST) and triglyceride (TG) levels 
among the groups, whereas the serum levels of FFA and 
IL-1β were significantly higher in the NASH patients 
compared with the normal healthy controls and NAFL 
patients, thus suggesting that the FFA and IL-1β levels are 
mainly associated with NASH but not NAFL.
In the NASH patients, liver ultrasonography showed 
increased echogenicity and unequal distribution, and 
computer tomographic images revealed normal sized 
but hypoechogenic livers, which is a typical imaging 
manifestation of NAFLD (Figure 1A). Hematoxylin-eosin 
(HE) and Oil Red O staining showed that the NAFL livers 
exhibited obvious steatosis, as compared with the normal 
livers (Figure 1B II vs I). The NASH livers had grades of 
steatosis similar to livers with NAFL (Figure 1B III vs II), 
whereas hepatocyte ballooning (Figure 1B III, arrows) and 
inflammatory cell infiltration (Figure 1B III, arrowheads) 
were more severe. Sirius Red staining showed that none 
of the groups exhibited liver fibrosis (Figure 1B, VII-IX). 
Immunohistochemical staining showed that the numbers 
of F4/80-, NLRP3- and TXNIP-positive cells were similar 
between the normal and NAFL groups (Figure 1C II vs I, 
V vs IV, VIII vs VII), whereas more F4/80-, NLRP3- and 
TXNIP-positive cells were observed in the NASH group as 
indicated by arrows than in the NAFL group (Figure 1C III, 
VI, IX, X-XII). The ultrastructures of the liver samples were 
examined through transmission electron microscopy (TEM), 
which revealed a significant increase in lipid droplets (arrows) 
in the hepatocyte cytoplasm accompanied by a compressed 
hepatic sinusoid in the NAFL group (Figure 1D II and V). 
Extreme hepatocyte oedema (arrowhead) filled with lipid 
droplets (arrow) was observed in the NASH group (Figure 
1D III). A fat-storing cell was found in a NASH liver sample 
(Figure 1D VI, arrowhead). Taken together, these results for 
human samples demonstrated that serum FFA might act as 
a type of danger-associated molecular pattern (DAMP) that 
activates TXNIP and the NLRP3 inflammasome in KCs and 
subsequently stimulates KCs to secrete IL-1β and promotes 
the progression from NAFL to NASH.
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NLRP3 and TXNIP are involved in the 
development of NAFLD in mice
We used diet-induced models of NAFL and NASH 
to detect the roles of NLRP3 and TXNIP in NAFL and 
NASH development. Immunohistochemical staining 
revealed a greater number of F4/80-, NLRP3- and TXNIP-
positive cells in the livers of WT mice in NASH group 
(arrows) than in normal and NAFL groups, whereas there 
were no significant differences in these cell populations 
between NAFL and normal groups (Figure 2A). Next, we 
used both NLRP3−/− and TXNIP−/− mice to determine the 
roles of NLRP3 and TXNIP during NAFLD development 
by using HFD-induced NAFL and MCD diet-induced 
NASH models. The body weights of the mice in our diet-
induced models were weekly determined (Supplementary 
Figure 1). There were no significant difference in body 
weights among the ND-fed WT, NLRP3−/− and TXNIP−/− 
mice (Figure 2B and 2C). NLRP3−/− mice gained less 
body weight than the WT mice after HFD feeding, while 
TXNIP−/− mice gained more body weight than the WT mice 
(Figure 2B and 2C). All animals fed MCD had decreased 
Figure 1: Human NASH is characterised by increased expressions of F4/80, NLRP3 and TXNIP. (A) Abdominal 
ultrasonography and CT scan images of normal, NAFL, and NASH patients. (B) HE, Oil Red O, and Sirius Red staining of liver sections 
(arrows, ballooning hepatocytes; arrowheads, inflammatory cells). (C) Immunohistochemical staining for F4/80, NLRP3 and TXNIP in 
liver sections (arrows, positive KCs). The quantitative immunohistochemical staining values (QISVs) were analysed for F4/80, NLRP3, 
and TXNIP protein expression (n = 5 for normal, n = 6 for NAFL, and n = 6 for NASH). *P < 0.05 for NASH vs NAFL and normal groups. 
(D) TEM images of human livers (arrows, lipid droplets; arrowhead in Panel III, hepatocyte oedema, in Panel VI, fat-storing cell). The 
original magnification is labeled in each picture.
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body weights (Figure 2B and 2C). Liver weights of WT 
mice in the HFD group were heavier than the livers from 
NLRP3−/− mice, whereas Liver weights of TXNIP−/− mice 
in the HFD group were heavier than the livers from WT 
mice. The liver weights in the MCD groups also decreased 
after intervention (Figure 2B and 2D). It is noticeable that 
TXNIP−/− mice gained more body and liver weight than the 
WT mice after HFD feeding (Figure 2B, 2C and 2D), thus 
indicating that TXNIP deficiency may aggravate NAFL 
severity. The FFA levels were all significantly elevated in 
these MCD groups, and there is no significant difference 
among these MCD groups (Figure 2E). In these MCD 
groups, NLRP3−/− mice showed the lowest IL-1β levels 
(Figure 2F). Nevertheless, the IL-1β levels in HFD and 
MCD groups of TXNIP−/− mice were significantly higher 
than those in the corresponding groups of WT mice, which 
also indicated that knocking out TXNIP can exacerbate 
liver injury, and this injury started from normal liver to 
NAFL (Figure 2F).
NLRP3 and TXNIP participate in different 
stages of NAFLD progression
No significant differences were observed in liver 
pathological characteristics among the three types of mice 
fed ND (Figure 3A, I, II, and III). Although HFD groups 
of WT and NLRP3−/− mice showed similar grades of liver 
steatosis (Figure 3B, I and II), hepatocyte ballooning and 
inflammatory cell infiltration were markedly attenuated 
in the MCD-fed group of NLRP3−/− mice (Figure 3C, II 
vs I, arrows, hepatocyte ballooning and inflammatory 
cells, arrowhead, normal area). Furthermore, we found 
that TXNIP−/− mice had a susceptibility to HFD, and the 
TXNIP−/− mice can be induced to NASH by HFD feeding 
alone, which is much more severe than HFD groups of 
WT mice and NLRP3−/− mice (Figure 3B, III vs I and II, 
arrow, hepatocyte ballooning). Interestingly, the main 
pathological characteristic of TXNIP−/− mice fed with 
HFD and MCD was hepatocyte ballooning (Figure 3B, 
III, Figure 3C, III), which is also a typical pathological 
characteristic of NASH in addition to inflammatory cell 
infiltration. This finding suggested that TXNIP might 
be mainly involved in the suppression of hepatocyte 
ballooning formation during the development of NASH. 
Sirius Red staining indicated that none of the groups 
displayed significant liver fibrosis (Figure 3A, 3B and 3C). 
In these MCD groups, NLRP3−/− mice showed the lowest 
values of plasma biomarkers of liver damage (ALT and 
AST). Nevertheless, the levels of ALT and AST in HFD 
group of TXNIP−/− mice were significantly higher than in 
the corresponding groups of WT mice, thus suggesting 
that TXNIP deficiency can exacerbate liver injury induced 
by HFD (Figure 3D and 3E). As expected, HFD and MCD 
feeding increased serum TG levels of WT mice, and there 
was no significant difference between the two groups. It is 
interesting that NLRP3 deficiency and TXNIP deficiency 
have no effect on the serum TG levels induced by HFD 
and MCD feeding (Figure 3F). Taken together, these 
results suggest that NLRP3 plays a pro-inflammatory role 
mainly in the progression from NAFL to NASH and that 
TXNIP has anti-inflammatory and protective effects from 
the stage of NAFL formation.
The ultrastructures of livers from WT mice were 
observed through TEM. In the ND group, the morphology 
and ultrastructures of the hepatocytes and the hepatic 
sinusoid were normal. Lipid droplets were apparent in 
hepatocytes, and the hepatic sinusoid was compressed in 
HFD group. In addition, the integrity of the hepatocytes 
and the hepatic sinusoid were destroyed in MCD livers 
(Supplementary Figure 2).
TXNIP and NLRP3 inflammasome participate 
in the progression of NASH through forming a 
protein complex
To investigate whether NLRP3 inflammasome 
complex is mainly activated in NASH, we performed Co-IP 
experiments. The results showed a very low level of protein 
Table 1: Comparison of the clinical and demographic factors
Characteristic Normal NAFL NASH
Case number 5 6 6
Age (years) 50 ± 7 48.2 ± 6.5 46 ± 6
Gender (male/female) 3/2 3/3 3/3
ALT (U/L) 15.33 ± 3.06 28.80 ±12.70 25.75 ±13.45
AST (U/L) 16.00 ± 1.73 24.40 ± 4.56 24.75 ± 12.45
TG (mmol/L) 0.76 ± 0.27 1.70 ± 1.21 1.90 ± 0.73
FFA (mmol/L) 0.63 ± 0.21 0.79 ± 0.11 2.11 ± 0.44*
IL-1β (ng/l) Non-detectable Non-detectable 27.23 ± 6.71*
NAS 0 2 ± 0.71 5 ± 0.82
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglycerides; FFA, free fatty acid; NAS, 
NASH activity score. *P < 0.05.
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Figure 2: KCs infiltration and expressions of NLRP3 and TXNIP are elevated in NASH livers of WT mice. (A) 
Immunohistochemical staining for F4/80, NLRP3 and TXNIP in liver sections (arrows, positive KCs). The quantitative immunohistochemical 
staining values (QISVs) were analysed for F4/80, NLRP3, and TXNIP protein expression. (B) Images of mice and liver phenotypes from 
WT, NLRP3−/− and TXNIP−/− mice fed ND, HFD or MCD diets. (C, D) Body and liver weights after intervention. (E, F) Serum FFA and 




complex formation in the KCs from WT mice in the normal 
and NAFL groups (Figure 4A), whereas a large amount of 
the complex was presented in the NASH group, and TXNIP 
is part of the complex (Figure 4B). These results indicated 
that TXNIP-NLRP3 inflammasome protein complex 
in KCs from WT mice contributed to the progression of 
NASH but not NAFL. We also investigated the potential 
relationship between TXNIP and NLRP3 in vitro. We used 
the KCs from WT mice stimulated with PA to investigate 
the interaction between TXNIP and NLRP3 by Co-IP. 
The results showed that the amount of TXNIP-NLRP3 
inflammasome protein complex was much greater in the 
Figure 3: NLRP3−/− mice exhibit reduced hepatocyte injury in MCD group and TXNIP knockout results in exacerbated 
hepatocyte injury after HFD feeding. (A, B, C) Images of HE, Oil Red O and Sirius Red staining of liver sections from WT, NLRP3−/− 
and TXNIP−/− mice fed ND, HFD or MCD diets. (D, E) Serum ALT and AST levels. (F) Serum TG levels. Data are expressed as the mean 
± SD. *represents P < 0.05 when comparing MCD groups of WT and TXNIP−/− genotypes with NLRP3−/− mice, #represents P < 0.05 when 
comparing HFD groups of TXNIP−/− genotypes with WT mice. The original magnification and scale bars are labeled in each picture.
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PA group than in the control (CON) group (Figure 4C). 
Furthermore, the high performance liquid chromatography-
mass spectrometry (LC-MS) results confirmed that TXNIP 
and NLRP3 were both detected in the IP groups and there 
were differences among the IP groups (Figure 4D).
TXNIP and NLRP3 inflammasome complex  
co-localize with the mitochondria in KCs 
To determine the essential role of mitochondria 
in the process of NLRP3 inflammasome activation, 
we evaluated the expressions of TXNIP and NLRP3 
inflammasome in the mitochondrial and cytosolic fractions 
of KCs by western blotting. The results showed that the 
expression levels of TXNIP and NLRP3 inflammasome 
were significantly elevated in the mitochondrial fraction 
of each group compared with the cytosolic fraction, 
thus suggesting that TXNIP and NLRP3 inflammasome 
mainly co-localized with the mitochondria after PA 
stimulation (Figure 4E, 4F). In the mitochondrial fraction, 
PA stimulation increased the expression of NLRP3 
inflammasome compared with that in CON group. The 
Figure 4: TXNIP-NLRP3 inflammasome complex is formed and co-localizes in the mitochondria in vivo and in vitro 
in WT mice. (A) Protein expressions levels as determined by Co-IP of TXNIP, NLRP3, ASC and Caspase-1 proteins from WT mice KCs 
of normal and NAFL groups. (B) Protein expressions levels as determined by Co-IP of TXNIP, NLRP3, ASC and Caspase-1 proteins from 
WT mice KCs of normal and NASH groups. (C) Co-IP of NLRP3 with TXNIP, ASC and Caspase-1 assessed by western blotting in KCs 
lysates from WT mice in the CON and PA groups. (D) Mass-spectrograms of NLRP3 and TXNIP. (E, F) Protein expression levels of TXNIP 
and NLRP3 inflammasome proteins in mitochondrial and cytosolic fractions. The histogram represents the mean ± SD of the densitometric 
scans for target protein bands normalized by comparison to COX4 or β-actin. *represents P < 0.05 when comparing PA with CON group. 
***represents P < 0.001 when comparing PA with CON group.
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expression of NLRP3 was minimal in resting KCs, and 
was clearly elevated in response to PA. The expression 
levels of ASC and Caspase-1 in the PA group were also 
higher than those in the CON group (Figure 4E, 4F). 
These results demonstrated that the TXNIP-NLRP3 
inflammasome complex mainly co-localized with 
mitochondria after PA stimulation.
TXNIP plays a protective role in the progression 
of NAFLD in vivo
As demonstrated in Figures 1 and 2, KCs play an 
important role in liver innate immunity. We next studied 
TXNIP and NLRP3 inflammasome protein expressions 
in KCs from livers of normal, NAFL and NASH mice 
to investigate the potential relationship between TXNIP 
and NLRP3. Our results showed that the expressions of 
TXNIP, NLRP3, ASC and Caspase-1 were all elevated 
in KCs from WT mice fed MCD diet, as compared with 
the levels in ND and HFD groups, whereas no significant 
differences were observed between ND and HFD groups 
(Figure 5A, 5D). These results suggested that TXNIP, 
NLRP3, ASC and Caspase-1 mainly participate in the 
progression from NAFL to NASH but not in the initiation 
of NAFL in WT mice and are consistent with the results 
described in Figures 1–4. Moreover, it is noticeable that 
TXNIP deficiency significantly increased the expressions 
of NLRP3, ASC and Caspase-1 in KCs from both HFD 
and MCD groups compared with corresponding groups 
of WT mice (Figure 5B, 5D). There were no increases in 
TXNIP or NLRP3 inflammasome expression in KCs from 
MCD-fed NLRP3−/− mice (Figure 5C, 5D). 
We further examined the effects of TXNIP and 
NLRP3 deficiency on NLRP3 inflammasome formation 
and activation in KCs from knockout mice by using Co-
IP. Unexpectedly, NLRP3 inflammasome was formed 
and activated in KCs from TXNIP−/− mice in the HFD 
group, and the activation of NLRP3 inflammasome was 
more apparent in KCs from TXNIP−/− mice in the MCD 
group (Figure 5E) than in KCs from WT mice (Figure 4B), 
Figure 5: NLRP3 inflammasome activation in KCs promotes NAFL to NASH progression. Analysis of isolated KCs from 
WT, TXNIP−/− and NLRP3−/− mice fed ND, HFD or MCD diets. TXNIP and NLRP3 inflammasome protein expressions in the KCs from 
(A) WT mice, (B) TXNIP−/− mice, and (C) NLRP3−/− mice. (D) Statistical analysis of protein expressions for TXNIP, NLRP3, ASC, 
and Caspase-1 in KCs from WT, TXNIP−/− and NLRP3−/− mice. (E, F) Protein concentration by Co-IP of TXNIP, NLRP3, ASC and 
Caspase-1 proteins in KCs from TXNIP−/− and NLRP3−/− mice. The histogram represents the mean ± SD of the densitometric scans for target 
protein bands normalized by comparison to β-actin. *represents P < 0.05 when comparing MCD with ND and HFD groups. **represents 
P < 0.01 when compare MCD with ND and HFD groups. #represents P < 0.05 when comparing HFD group of TXNIP−/− mice with WT mice. 
## represents P < 0.01 when comparing HFD groups of TXNIP−/− mice with WT mice. & represents P < 0.05 vs corresponding groups of 
WT mice.
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whereas NLRP3 protein complex expression decreased 
significantly in the KCs from NLRP3−/− mice (Figure 5F). 
Taken together, these results demonstrated that NLRP3 
was essential for NLRP3 inflammasome activation 
in KCs in a MCD-diet induced NASH model, and that 
TXNIP suppressed NLRP3 inflammasome formation and 
activation in KCs from WT mice fed by HFD and MCD 
diet, as evidenced by the result that TXNIP knockout 
significantly up-regulated the expression and activation 
NLRP3 inflammasome in KCs, which could explain the 
results in Figure 3B that TXNIP knockout can lead to 
NASH from HFD alone.
TXNIP inhibits NLRP3 inflammasome activation 
and IL-1β secretion in vitro
We isolated and cultured KCs from WT, NLRP3−/− 
and TXNIP−/− mice in the absence or presence of PA, an 
established NLRP3 activator, to evaluate the protective 
role of TXNIP on the progression of NAFLD in vitro 
by analyzing the expressions of NLRP3 inflammasome 
components and IL-1β secretion in KCs. We found 
that PA increased TXNIP, NLRP3, ASC and Caspase-1 
protein levels in the KCs of WT mice (Figure 6A and 
6B). Interestingly, PA induced a greater up-regulation of 
NLRP3, ASC and Caspase-1 protein levels in the KCs from 
TXNIP−/− mice than in those from WT mice (Figure 6A and 
6B), thus supporting the result from in vivo experiments 
that TXNIP provides a protective role by suppressing 
NLRP3 protein expression induced by FFA. As expected, 
PA had no effect on ASC and Caspase-1 protein expression 
in the KCs from NLRP3−/− mice (Figure 6A and 6C). 
We also found that caspase-1 activity was 
significantly increased in the KCs from WT and TXNIP−/− 
mice stimulated by PA, and the level in PA group of 
TXNIP−/− group was higher than WT group (Figure 6D). 
In agreement with the increased inflammasome expression 
and caspase-1 activity, IL-1β secretion was significantly 
increased in the supernatant (SN) of KCs from WT mice 
subjected to PA treatment. As a consequence of TXNIP 
knockout, the level of IL-1β in PA group was higher 
than PA group of WT mice. There were no significant 
differences between CON and PA groups in the SN of KCs 
from NLRP3−/− mice (Figure 6E). In order to investigate 
the consequence in terms of pyroptosis, we determined 
the percentage of cell death in KCs from WT, TXNIP−/−, 
and NLRP3−/− mice with or without PA stimulation. As 
expected, PA could trigger pyroptosis in KCs from WT 
mice. TXNIP deficiency exacerbates pyroptosis in KCs 
under PA stimulation, whereas there is no significant 
difference between the control and PA groups in KCs from 
NLRP3−/− mice (Figure 6F). 
Finally, the immunofluorescence results showed that 
PA stimulation increased the expressions and co-localization 
of NLRP3 inflammasome in KCs from WT mice (Figure 
7A, 7D, 7I, arrows, co-localization of NLRP3, ASC and 
Caspase-1). More importantly, the results revealed a much 
more co-localization in PA-stimulated KCs from TXNIP−/− 
Figure 6: TXNIP inhibits NLRP3 inflammasome activation and IL-1β secretion in vitro. (A) TXNIP and NLRP3 
inflammasome protein expressions in KCs of (B) WT and TXNIP−/− and (C) WT and NLRP3−/− mice. (D) Caspase-1 activity in KCs. (E) IL-
1β levels in the supernatant (SN) from KCs of WT, TXNIP−/− and NLRP3−/− mice. (F) NLRP3 deficiency blocks pyroptosis. The histogram 
represents the mean ± SD of the densitometric scans for target protein bands normalized by comparison to β-actin. ***represents P < 0.001, 
when comparing PA group with CON for each genotypic group. #represents P < 0.05 when comparing PA groups of TXNIP−/− group with the 
corresponding WT group. ##represents P < 0.01 when comparing PA groups of TXNIP−/− group with the corresponding WT group. 
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mice compared with those from WT mice (Figure 7B, 7D, 
II, arrows, co-localization of NLRP3, ASC and Caspase-1). 
As expected, PA stimulation had no obvious effect on KCs 
from NLRP3−/− mice (Figure 7C, 7D, III). Taken together, 
these results demonstrated that PA mechanistically acts as a 
DAMP and increases the expressions of TXNIP and NLRP3 
inflammasome as well as IL-1β secretion in KCs. Moreover, 
NLRP3 was indispensable for PA-induced inflammasome 
activation. In contrast, TXNIP exerted an anti-inflammatory 
effect in this process by suppressing the expression of 
NLRP3. Our observations in NASH mice models and 
PA-stimulated KCs were consistent with the NLRP3 
inflammasome activation observed in human samples.
DISCUSSION
NASH is an increasing cause of liver disease 
necessitating liver transplantation and predicted to become 
the primary indication for liver transplantation by 2020 
[2, 3]. The pathogenesis of NASH has been linked to 
multiple mechanisms, including dietary and environmental 
factors, and genetics which can affect innate immunity, 
inflammation, hepatocellular injury and cell death 
[1]. Maintaining a balance between the activation and 
inhibition of inflammatory pathways is extremely 
important to allow the immune system to remove any 
sources of danger, without causing detrimental harm to the 
host [8]. The NLRP3 inflammasome and IL-1β signalling 
pathways in KCs have been shown to play essential roles 
in NASH pathogenesis [8].
In the present study, we found that FFA, as a 
mechanistic activator of NLRP3 inflammasome, activated 
NLRP3 inflammasome and induced IL-1β secretion in 
KCs and that the expression of NLRP3 increased in liver 
tissues and was accompanied by elevated levels of FFA 
and IL-1β in serum of NASH patients and MCD induced 
mice model. Furthermore, we explored the important 
mechanisms by which TXNIP and NLRP3 inflammasome 
regulate inflammatory responses during NAFLD 
progression, and we found that the NLRP3 inflammasome 
and IL-1β secretion pathway in KCs were mainly activated 
during the progression from NAFL to NASH in WT 
mice, rather than from normal liver to NAFL. However, 
TXNIP deficiency can exacerbate mice NAFL induced 
by HFD alone and lead to NASH formation, which was 
probably caused by losing the TXNIP suppression effect 
on NLRP3 and then NLRP3 inflammasome activation 
in the KCs from TXNIP−/− mice. Consequently, we 
deemed that TXNIP in KCs played a protective and 
anti-inflammatory role by binding to and suppressing 
the expression of NLRP3. The in vitro results indicated 
that NLRP3 and TXNIP had opposite functions during 
NLRP3 inflammasome activation and IL-1β secretion in 
KCs induced by PA, which was in accordance with the 
in vivo findings. Previous studies have suggested a central 
role of mitochondria in NLRP3 inflammasome activation 
[22]. In addition to providing an ideal platform for the 
assembly of NLRP3 inflammasome, mitochondria release 
danger molecules such as mitochondrial DNA (mtDNA) 
and cardiolipin, which are able to bind and activate the 
NLRP3 inflammasome through ROS-dependent and ROS-
independent pathways, respectively [23–25]. In this study, 
we also demonstrated that TXNIP and components of the 
NLRP3 inflammasome are mainly bound to mitochondria 
in KCs after PA treatment, thus suggesting that the NLRP3 
inflammasome probably associate with an essential 
molecule released from mitochondria in response to 
NLRP3 activators.
The role and function of the NLRP3 inflammasome 
in the MCD diet-induced NASH model are controversial. 
Consistent with our results, it has been reported that 
activation of the NLRP3 inflammasome in hepatocytes 
and liver mononuclear cells promotes the progression of 
NASH [11]. However, Henao-Mejia et al. have reported 
that mice knockout in NLRP3, ASC, or Caspase-1 
developed more severe steatosis and inflammation when 
they are fed with MCD diet [21]. The authors concluded 
that genetic inflammasome deficiency-associated dysbiosis 
resulted in abnormal accumulation of bacterial products 
in the portal circulation. The liver, which is the “first 
pass” organ and thus exposed to the highest concentration 
of portal system products such as pathogen-associated 
molecular patterns (PAMPs), is expected to be most 
vulnerable to the effects of these molecules [21]. A tissue-
specific knockout model may be required to specify the 
role of NLRP3 inflammasome activation in future studies.
A large number of DAMPs and PAMPs can activate 
NLRP3 inflammasome. Given the structural diversity 
of these agonists, it is difficult to find that NLRP3 can 
directly recognize and associate with all of these DAMPs 
and PAMPs [26]. Therefore, the mechanisms by which 
these distinct agonists activate NLRP3 inflammasome 
are currently unclear and have recently been debated, 
although it is generally accepted that there are likely to 
be several cofactors involved in NLRP3 inflammasome 
activation [22, 27]. The role of TXNIP plays in NAFLD 
development and NLRP3 activation is unclear and has not 
been widely explored. It has been reported that following 
an increase in ROS induced by NLRP3 activators, TXNIP 
dissociates from TRX and binds to NLRP3, leading to 
NLRP3 activation, and TXNIP knockout impairs NLRP3 
inflammasome activation and IL-1β secretion in bone 
marrow macrophages after stimulation with NLRP3 
agonists [18]. Zhang et al. reported that TXNIP silencing 
blocked NLRP3 inflammasome activation and lipid 
metabolism perturbations in fructose-exposed hepatocytes, 
whereas antioxidants addition abrogated TXNIP induction 
and diminished the detrimental effects in fructose-exposed 
hepatocytes and rat livers [28]. However, our results 
both in vivo and in vitro showed that TXNIP deficiency 
exacerbated NAFL and resulted in NASH formation, and 
that NLRP3 inflammasome activation and IL-1β secretion 
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Figure 7: TXNIP deficiency enhances the co-localization of NLRP3, ASC and Caspase-1 in KCs. NLRP3 inflammasome 
formation in KCs as shown by confocal microscopy from (A) WT, (B) TXNIP−/−, and (C) NLRP3−/− mice (arrows, co-localization of 
NLRP3, ASC and Caspase-1). (D) The Mander’s overlap coefficient values were analysed for the degree of co-localization. ***represents 
P < 0.001, when comparing PA group with CON group. ##represents P < 0.01 when comparing PA groups of TXNIP−/− group with the 
corresponding WT group. Scale bars are labeled in each picture.
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in KCs were not blocked but were enhanced in the absence 
of TXNIP, thus suggesting that TXNIP suppresses the 
expression and function of NLRP3 inflammasome by 
binding to NLRP3.
In summary, the present study demonstrates that 
TXNIP, NLRP3 inflammasome activation, and subsequent 
IL-1β secretion in KCs are involved in NAFLD 
development. TXNIP and NLRP3 play opposite roles 
during different stages of NAFLD development. TXNIP 
plays a protective and anti-inflammatory role by binding 
and suppressing NLRP3 mainly during the formation of 
NAFL, whereas NLRP3 plays a pro-inflammatory role 
in the progression of NASH. Our findings reveal novel 
links between TXNIP and NLRP3 and suggest potential 
therapeutic targets for NAFLD progression.
MATERIALS AND METHODS
Human samples
This study was conducted in accordance with the 
ethical guidelines of the 1975 Declaration of Helsinki 
and was approved by the Committee for Human Subjects 
of Chongqing Medical University. Informed consent 
was obtained from all subjects. Human liver samples 
(n = 17) were obtained from patients with suspected 
NAFLD. The NAFLD diagnoses were provided by two 
pathologists according to the NAFLD activity score 
(NAS) system [29].
Animals and diets
TXNIP−/− and NLRP3−/− male mice aged 8 weeks 
purchased from Jackson Laboratories (Bar Harbor, ME, 
USA) were bred in the laboratory animal research centre 
of Chongqing Medical University (Chongqing, China). 
WT C57BL/6 mice were obtained from the laboratory 
animal research centre of Chongqing Medical University. 
WT, TXNIP−/− and NLRP3−/− mice were divided into 
three dietary groups: normal diet (ND) or HFD (D12492, 
Research Diets, USA) for 8 weeks or MCD diet 
(A02082002B, Research Diets, USA) for 4 weeks. Each 
of these nine groups contained 6 mice. The KCs of the 
above groups were isolated and directly analysed. For 
in vitro studies, we purified and cultured primary KCs 
from a second batch of WT, TXNIP−/− and NLRP3−/− mice 
fed with ND (n = 6 animals per experimental group). 
All animals were housed under specific-pathogen-free 
conditions and received humane care in compliance with 
the guidelines of the institution as outlined in the guide 
for the care and use of laboratory animals prepared by 
the National Academy of Sciences, and the methods were 
carried out in accordance with the relevant guidelines. 
The experimental protocols were approved by the 
committee for animal experimentation at Chongqing 
Medical University. 
Histological analysis
Sections of formalin-fixed livers were stained 
with hematoxylin-eosin (HE), Oil Red O, Sirius Red, 
and immunohistochemical staining for F4/80 (ab16911, 
Abcam, UK), NLRP3 (sc-66846, Santa Cruz, USA) and 
TXNIP (sc-33099, Santa Cruz, USA). The quantitative 
immunohistochemical staining values (QISVs) were 
calculated as the integrated OD divided by the total 
area occupied by the brown cells in each slide. The 
ultrastructures of the liver tissue were observed using a 
transmission electron microscopy (TEM, Hitachi, Japan). 
Serum analysis
Serum aminotransferase levels were determined 
according to the rate method. Serum levels of FFA were 
measured using an enzymatic method (Clinimate NEFA 
kit, Sekisui Medical Company, Japan). Serum IL-1β 
levels were determined by chemiluminescence (BioRad, 
USA). Serum lipid level was measured with enzymatic 
color tests (serum triglyceride determination kit, Sigma-
Aldrich, UK).
In vitro experiments
Primary KCs isolated from WT, TXNIP−/− and 
NLRP3−/− mice livers were cultured as previously 
described [30]. Cell viability (> 90%) was evaluated by 
trypan blue exclusion and KC phagocytic activity was 
determined by ink swallowing experiment. KCs were 
randomly divided into two groups: control group (CON 
group) and PA group (palmitic acid, 0.32 mM). The cells 
were starved for 12 h and stimulated for an additional 
12 h. Then, inflammasome proteins and their interactions 
were further analysed. 
Mitochondria/cytosol protein fractionation 
analysis
The mitochondrial and cytosolic KC fractions were 
extracted using a ProteoExtract® Cytosol/Mitochondria 
Fractionation Kit (QIA88, Millipore, Calbiochem, 
USA) as per manufacturers’ instructions. Cytochrome C 
oxidase subunit 4 (COX4) was used as the control for the 
mitochondrial fraction. Equivalent protein amounts from 
the cytosolic and mitochondrial fractions were analysed 
by western blotting.
Western blotting
Total protein was extracted in cell lysis buffer 
(R0278, RIPA buffer, Sigma, UK) and the protein 
concentration was determined. The protein concentration 
was determined with a BCA Protein Assay Kit (23227, 
Thermo, UK). Equal amounts of proteins per sample 
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were separated by electrophoresis and transferred onto 
polyvinylidene fluoride membranes. The membranes 
were then blocked for 1 h with 5% albumin bovine and 
incubated with primary antibodies specific for TXNIP 
(sc-33099, Santa Cruz, USA), NLRP3 (sc-66846, Santa 
Cruz, USA), ASC (sc-22514-R, Santa Cruz, USA) and 
Caspase-1 (sc-56036, Santa Cruz, USA) at 4°C overnight. 
The membranes were washed and incubated with the 
secondary antibodies. Protein expression was assessed 
by chemiluminescence. Relative amounts of protein were 
quantified based on the relative densities of the protein 
bands, by using an image analysis system (Bio-Rad Gel 
Doc 2000, USA). 
Co-immunoprecipitation
The interactions between TXNIP and NLRP3 
inflammasome proteins in KCs were analysed by co-
immunoprecipitation (Co-IP). Briefly, total protein was 
extracted in cell IP lysis buffer (87787, Thermo Scientific 
Pierce, USA). The protein concentration was determined 
with a BCA Protein Assay Kit (23227, Thermo, UK), 
and consistent protein amounts were used for each 
group. Then, each sample was equally divided into IP 
and IgG groups, and 500 µg of protein in each of the 
IP and IgG groups was incubated with 5 μg of NLRP3 
or 5 μg IgG antibody (AP162, Millipore, USA) at 4°C 
overnight with continuous mixing. Fifty microliters of 
PureProteome Protein A Magnetic Beads (LSKMAGA10, 
Millipore, USA) was washed with PBST and added to the 
lysed pre-formed antibody-antigen complex. The mixture 
was incubated for 2 h at room temperature with continuous 
mixing to capture the immune complex, and the immune 
complex was then separated from the magnetic beads 
by heating at 95°C for 10 min. Finally, the interactions 
between TXNIP and NLRP3 in the inflammasome were 
detected by western blot analysis as described above.
Nano-LC-MS/MS analysis and protein 
identification
High performance liquid chromatography-mass 
spectrometry (LC-MS) was used to confirm the Co-IP 
results and to identify other potential molecules. Protein 
bands of interest were excised from the Coomassie 
blue-stained gel. Each gel slice was diced into small 
particles (1mm*1mm*1mm) and placed into a 96-well 
plate. Sample preparation was followed the standard 
protocol as described previously [31]. Gel slices were 
de-stained and digested with sequencing grade trypsin 
(Promega, USA) at 37°C overnight. The protein digests 
were extracted, lyophilized and re-dissolved for nano-
LC-MS/MS analysis, which were performed using 
the Q-Exactive (Thermo Scientific). The Maxquant 
Software was applied for protein identification and 
quantitation.
Caspase-1 activity assay and cytotoxicity assays
Caspase-1 activity in KCs was determined with a 
colorimetric assay (R&D Systems, USA). Cell death was 
determined by the lactate dehydrogenase release assay 
using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit 
(Promega) according to the manufacturer’s instructions.
Immunofluorescence analysis
The protein expression levels of NLRP3, ASC and 
Caspase-1 in KCs were detected by immunofluorescence 
(IF). IF was performed according to the manufacturer’s 
instructions. In detail, the cells were fixed with 4% 
paraformaldehyde for 15 min and then permeated in 0.2% 
Triton X-100 in PBS for 10 min. The cells were then 
blocked with 10% serum in PBS for 1 h and incubated with 
the primary antibody described above (1:200) overnight 
at 4°C. The cells were then incubated with the secondary 
antibody (1:200) (Alexa Fluor® 488 conjugate, Alexa Fluor® 
555 conjugate, Alexa Fluor® 647 conjugate secondary 
antibody, Invitrogen, UK) for 1 h. After been washed with 
PBS, the cells were covered with the mounting medium, 
and the slides were viewed by a confocal microscopy 
(Nikon, A1+, Japan), ensuring non-saturating identical 
equipment settings for intensity comparisons among 
different groups. The Mander’s overlap coefficient values 
were analysed for the degree of co-localization. 
Statistical analysis
The values are expressed as the mean ± SD (standard 
deviation) and compared by one-way ANOVA followed by 
Tukey post-hoc test when significant for the comparisons 
of interest using the SPSS statistical package, version 18.0 
(International Business Machines, Armonk, NY, USA). 
P < 0.05 was considered to be significant.
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